# Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans

> **NCT07646080** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yanjie Zhang, MD** · enrollment: 20 (estimated)

## Conditions studied

- Dermatofibrosarcoma Protuberans (DFSP)

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Anlotinib
- **DRUG:** Standard Chemotherapy

## Key facts

- **NCT ID:** NCT07646080
- **Lead sponsor:** Yanjie Zhang, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07646080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07646080, "Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07646080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*